Download Files:
Bcl-xL antagonist 2
$450 – $3,800
Products Details
Product Description
– Bcl-xL antagonist 2 is a potent, selective, and orally active antagonist of BCL-XL with an IC50 and Ki of 0.091 μM and 65 nM, respectively. Bcl-xL antagonist 2 promotes the apoptosis of cancer cells. Bcl-xL antagonist 2 has the potential for the research of the chronic lymphocytic leukemia (CLL) and non-Hodgkin’s lymphoma (NHL)[1][2].
Web ID
– HY-12908
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Cancer-programmed cell death
Molecular Formula
– C21H16N4O3S2
References
– [1]Koehler MF, et al. Structure-Guided Rescaffolding of Selective Antagonists of BCL-XL. ACS Med Chem Lett. 2014;5(6):662-667.|[2]Wang L, et al. Discovery of A-1331852, a First-in-Class, Potent, and Orally-Bioavailable BCL-XL Inhibitor. ACS Med Chem Lett. 2020;11(10):1829-1836.
CAS Number
– 1235032-75-3
Molecular Weight
– 436.51
Compound Purity
– 98.46
SMILES
– O=C(C1=C(CN(C2=NC(C(O)=O)=CS2)CC3)C3=CC=C1)NC4=NC5=C(S4)C=CC=C5
Clinical Information
– No Development Reported
Research Area
– Cancer
Solubility
– DMSO : 62.5 mg/mL (ultrasonic)
Target
– Apoptosis;Bcl-2 Family
Pathway
– Apoptosis
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
